GENEART Awarded European Patent for Tested HIV Vaccines
News Apr 09, 2008
The GENEART AG announces the award of the patent EP 1240333 titled "Das Genom des HIV-1 Intersubtyps (C/B') und seine Anwendungen" ("The Genome of HIV-1 Intersubtype (C/B') and Use Thereof") by the European Patent Office.
The above-mentioned patent protects the use of certain custom-designed HIV gene sequences for the development of therapeutics or vaccines in the following countries: Austria, Belgium, France, Germany, Great Britain, Italy, Luxembourg, the Netherlands, Spain and Switzerland. The US American patent of the patent family was already assigned in February.
The patent describes gene sequences, which have already been successfully tested as HIV vaccine candidates in a phase I clinical trial. The results of the clinical trial have been published in "The Journal of Experimental Medicine" (Vol. 205, 63-77).
Currently, the gene sequences are tested in a phase I/II trial by the EuroVacc Foundation. As a licensor, GENEART provides the patented gene sequences (structural design) for these trials.
Largest Genetic Study of Osteoarthritis Advances ResearchNews
Osteoarthritis is a complex disease, and the genetic basis of the disease has proved difficult to pin down. A new study from the Sanger Institute provides much-needed hope.READ MORE
The DNA Shuffle: Barcoding Trick is Boost to RNA-SeqNews
SPLiT-seq is a new technology that can separate thousands of cells using innovative barcoding technology.READ MORE
Comments | 0 ADD COMMENT
11th International Conference and Exhibition on Metabolomics & Systems Biology
May 17 - May 19, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018